Author’s response to reviews

Title: PUREAIR PROTOCOL: RANDOMIZED CONTROLLED TRIAL OF INTENSIVE PULMONARY REHABILITATION VERSUS STANDARD CARE IN PATIENTS UNDERGOING SURGICAL RESECTION FOR LUNG CANCER. EFFECTS ON EXERCISE TOLERANCE, LUNG FUNCTION, POSTOPERATIVE COMPLICATIONS AND QUALITY OF LIFE

Authors:

Stefania Fugazzaro (stefania.fugazzaro@asmn.re.it)

stefania costi (stefania.costi@unimore.it)

Carlotta Mainini (carlotta.mainini@asmn.re.it)

Besa Kopliku (besa.kopliku@asmn.re.it)

Cristian Rapicetta (cristian.rapicetta@asmn.re.it)

Roberto Piro (roberto.piro@asmn.re.it)

Roberta Bardelli (roberta.bardelli@asmn.re.it)

Patricia Sobral Rebelo (patriciafsrebelo@gmail.com)

Carla Galeone (carla.galeone@asmn.re.it)

Giorgio Sgarbi (giorgio.sgarbi@asmn.re.it)

Filippo Lococo (filippo.lococo@asmn.re.it)

Massimiliano Paci (massimiliano.paci@asmn.re.it)

Tommaso Ricchetti (tommaso.ricchetti@asmn.re.it)

Silvio Cavuto (silvio.cavuto@asmn.re.it)

Domenico Merlo (domenico.merlo@asmn.re.it)

Sara Tenconi (sara.tenconi@asmn.re.it)

Version: 1 Date: 21 Jun 2017

Author’s response to reviews:
Dear Editor-in-Chief,

Attached please find the revised manuscript titled “PuReAIR Protocol: Randomized Controlled Trial of Intensive Pulmonary Rehabilitation versus Standard Care in patients undergoing surgical resection for Lung Cancer. Effects on Exercise Tolerance, Lung Function, Postoperative Complications and Quality of Life” by Fugazzaro S et al., that I would like to submit for publication in the BMC Cancer.

We addressed all the question raised in the e-mail received on June 8th, 2017 as follows:

1. Consent to participate.

The consent to participate was in written form, as required by law. Therefore, as suggested, we specified in the main text that the consent was in written form (Methods/ Participants and setting section, line 191, page 7) and in the “Ethics approval and consent to participate” session of “Declarations”.

2. Ethical and Funding Approval Documentation.

We forwarded the ethical approval and funding approval to the Editorial office (BMCSeriesEditorial@biomedcentral.com) on June 20, 2017. As requested, we provided the original documentation in Italian language and, for any document, we also sent a translated version of the relevant parts, endorsed and signed by the Scientific Director of the Institute.

3. Funding

We declared that the study protocol has undergone peer-review process by the Italian Ministry of Health, which is the funding body, in the “Funding” session of “Declarations”.

4. Study status

We declared that the study is currently enrolling patients in the “Study status” session of “Declarations”.

5. Related articles

We listed the Conferences where preliminary data regarding this study has been presented in the form of abstract/poster in the “Related article” session of “Declaration”. However, the results of the study have never been presented anywhere, neither have been submitted or published data regarding this study to any journal.

Thank you for considering the submission to BMC Cancer and let me know of your decision at your earliest convenience.

Distinct regards,

On behalf of all authors

Stefania Costi, MSc in PT